AirXpanders to Host Modernizing Breast Reconstruction Symposium at Plastic Surgery The Meeting
SAN JOSE, Calif.--(BUSINESS WIRE)--Sep 25, 2018--AirXpanders, Inc. today announced a series of activities at the American Society of Plastic Surgeons’ (ASPS) Plastic Surgery The Meeting in Chicago. The company will host a “Modernizing Breast Reconstruction: A Multidisciplinary Approach Using a Needle-Free CO 2 Tissue Expander” symposium on Sunday, September 30 from 12:15-1:15 p.m. CST at McCormick Place West, room number W474A. Leading surgeons including Laura Sudarsky, M.D., Cristiano Boneti, M.D., Thomas McNemar, M.D., and Martin Keisch, M.D. will discuss clinical outcomes using the AeroForm Tissue Expander. To register for the symposium, contact Laurel Burk at firstname.lastname@example.org.
“September has been an important month for the company. We recently announced a round of financing and we’re looking forward to continuing the momentum at this year’s ASPS meeting,” said Frank Grillo, President & CEO, AirXpanders. “Our team is excited to host this multidisciplinary symposium demonstrating the clinical outcomes of the AeroForm technology. AeroForm is the first major advancement in tissue expansion for breast reconstruction in 40 years, and we are enthusiastic about providing an approach that places control back into the patient’s hands.”
The AeroForm Tissue Expander System offers a needle-free alternative for women who choose reconstructive surgery with implants following a mastectomy. Developed by a plastic surgeon, the AeroForm Tissue Expander is surgically inserted either underneath or above the chest muscle. It is activated by a handheld wireless controller that triggers a valve to release small amounts of carbon dioxide (CO 2 ), up to three times a day, to gradually stretch the tissue and prepare for insertion of a breast implant. With the push of a button from the wireless controller, a pre-programmed amount of CO 2 is delivered in seconds, allowing women to continue with their daily activities while preparing for reconstruction.
In addition to the symposium, Tripp Holton, M.D. of Anne Arundel Medical Center will present during the Resident’s Day Program “The Advancements in Breast Reconstruction with a Novel CO 2 Needle-Free Tissue Expander,” on September 28 at 9:25 a.m. CST. “The AeroForm Expander has changed my practice. It has freed me to focus on actual patient care and spared me from the complications associated with saline expansion,” said Dr. Holton. “More importantly, it has unchained my patients from my office and invested them with a refreshing sense of autonomy. That means that these women are partners more than patients.”
Additional information about the AeroForm system will be discussed by Devinder Singh, M.D. of Anne Arundel Medical Center, on behalf of Tony Connell, M.D. during the Scientific Abstract Presentations: Breast 3, scheduled for October 1, 10:30 a.m. – 12:00 p.m. CST.
Founded in 2005, AirXpanders, Inc. designs, manufactures and markets innovative medical devices to improve breast reconstruction. The AeroForm Tissue Expander System is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in San Jose, California, AirXpanders’ vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publicly listed Company on the Australian Securities Exchange under the symbol “AXP.” AeroForm received its first CE mark in Europe in 2012 and TGA clearance for commercialization in Australia in 2013. It was granted U.S. FDA de novo marketing authorization in 2016, and subsequent U.S. market 510k clearance in 2017. For more information, refer to the Company’s website at www.airxpanders.com
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.
All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its most recent Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on July 31, 2018, including under the caption “Risk Factors,” as well as other periodic reports filed with the SEC. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005418/en/
CONTACT: for AirXpanders, Inc.
Karen Serpa, 415-676-1923
Director of Marketing, 650-282-8117
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA ILLINOIS
INDUSTRY KEYWORD: SURGERY HEALTH MEDICAL DEVICES
SOURCE: AirXpanders, Inc.
Copyright Business Wire 2018.
PUB: 09/25/2018 08:00 AM/DISC: 09/25/2018 08:01 AM